Clinical Trials Logo

Fallopian Tube Neoplasms clinical trials

View clinical trials related to Fallopian Tube Neoplasms.

Filter by:

NCT ID: NCT05257408 Active, not recruiting - Clinical trials for Peritoneal Neoplasms

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Start date: June 29, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

NCT ID: NCT05256576 Recruiting - Frailty Clinical Trials

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer

KORE
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

KORE-Innovation is a multi-center clinical study aiming to implement and analyze an innovative care pathway to reduce perioperative complications for patients undergoing surgical treatment for ovarian cancer. This is achieved by a structured, multidisciplinary implementation of the ERAS pathway, as well as introducing a tri-modal prehabilitation program, following a comprehensive frailty-assessment. The patient-individualized prehabilitation program consists of a structured plan to improve physical fitness, nutritional status, as well as patient empowerment. The aim of the study is to reduce perioperative morbidity and mortality, as well as improvement in quality of life.

NCT ID: NCT05236686 Not yet recruiting - Clinical trials for Fallopian Tube Cancer

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Start date: February 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.

NCT ID: NCT05220033 Recruiting - Ovarian Cancer Clinical Trials

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Start date: July 14, 2020
Phase: N/A
Study type: Interventional

This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.

NCT ID: NCT05200364 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

NCT ID: NCT05200260 Not yet recruiting - Ovarian Cancer Clinical Trials

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Start date: February 2022
Phase: Phase 2
Study type: Interventional

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

NCT ID: NCT05199272 Active, not recruiting - Solid Tumor Clinical Trials

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Start date: December 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

NCT ID: NCT05198804 Recruiting - Ovarian Cancer Clinical Trials

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Start date: January 27, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer.

NCT ID: NCT05194072 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of SGN-B7H4V in Advanced Solid Tumors

Start date: January 12, 2022
Phase: Phase 1
Study type: Interventional

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers.

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.